Truist lowered the firm’s price target on Inspire Medical (INSP) to $235 from $250 and keeps a Buy rating on the shares. The company’s Q4 results saw a “solid” earnings and gross margin beat, though its profit upside may get overshadowed by a DOJ civil investigative demand, the analyst tells investors in a research note. This could weigh on shares temporarily, but given Inspire’s inflecting profitability and positive cash position, it should be manageable for the stock, Truist added.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $248 from $252 at Baird
- Inspire Medical price target lowered to $220 from $230 at Morgan Stanley
- Inspire Medical price target lowered to $195 from $198 at Wells Fargo
- Inspire Medical Systems: Balancing Strong Performance with Operational Challenges and Regulatory Risks
- Inspire Medical Systems: Strong Buy Rating Amid Growth Prospects and DOJ Investigation Challenges